PMID- 34749627
OWN - NLM
STAT- MEDLINE
DCOM- 20220523
LR  - 20220622
IS  - 1875-5992 (Electronic)
IS  - 1871-5206 (Linking)
VI  - 22
IP  - 11
DP  - 2022
TI  - Regulation of Cell Death Mechanisms by Melatonin: Implications in Cancer Therapy.
PG  - 2080-2090
LID - 10.2174/1871520621999211108090712 [doi]
AB  - Cancer therapy is based on the killing of cancer cells using various therapeutic 
      agents, such as radiation, chemotherapy or targeted therapy drugs, and 
      immunotherapy. Cancer cells may undergo apoptosis, mitotic catastrophe, necrosis, 
      autophagy, mitophagy, senescence, etc., depending on the therapeutic modality and 
      nature of cancer cells. Mutations in some critical genes, such as p53 and 
      Phosphatase and Tensin Homolog (PTEN) tumor suppressor genes, are associated with 
      immune escape of cancer cells and tumor progression. Furthermore, the 
      overexpression of some genes. such as phosphatidylinositol-3-kinase (PI3K), 
      Nuclear Factor of Kappa B (NF-kappaB), cyclooxygenase-2 (COX-2) and mammalian Target 
      of Rapamycin (mTOR), is associated with the resistance of cancer cells to various 
      types of cell death. Melatonin is known as a circadian regulator hormone that has 
      several anti-cancer properties. It has the ability to activate tumor suppressor 
      genes and attenuate the expression of survival genes in cancer cells. Modulation 
      of cell death or survival genes that have been disrupted or overexpressed in 
      cancer cells can improve cancer therapy. In this review, we explain the potential 
      of melatonin in regulating various mechanisms of cancer cell death.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Wang, Zicheng
AU  - Wang Z
AD  - Department of TCM, The Affiliated Hospital of Yangzhou University, Yangzhou, 
      Jiangsu, 225000, China.
FAU - Liu, Yanqing
AU  - Liu Y
AD  - Department of TCM, The Affiliated Hospital of Yangzhou University, Yangzhou, 
      Jiangsu, 225000, China.
FAU - Musa, Ahmed Eleojo
AU  - Musa AE
AD  - Department of Medical Physics, Tehran University of Medical Sciences, Tehran, 
      Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Anticancer Agents Med Chem
JT  - Anti-cancer agents in medicinal chemistry
JID - 101265649
RN  - 0 (NF-kappa B)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - JL5DK93RCL (Melatonin)
SB  - IM
MH  - Apoptosis
MH  - Autophagy
MH  - Humans
MH  - *Melatonin/pharmacology
MH  - NF-kappa B/metabolism
MH  - *Neoplasms/drug therapy
MH  - PTEN Phosphohydrolase
MH  - Proto-Oncogene Proteins c-akt/metabolism
OTO - NOTNLM
OT  - Melatonin
OT  - apoptosis
OT  - autophagy
OT  - cancer
OT  - mitotic catastrophe
OT  - senescence
EDAT- 2021/11/10 06:00
MHDA- 2022/05/24 06:00
CRDT- 2021/11/09 05:35
PHST- 2021/04/20 00:00 [received]
PHST- 2021/07/26 00:00 [revised]
PHST- 2021/08/23 00:00 [accepted]
PHST- 2021/11/10 06:00 [pubmed]
PHST- 2022/05/24 06:00 [medline]
PHST- 2021/11/09 05:35 [entrez]
AID - ACAMC-EPUB-118736 [pii]
AID - 10.2174/1871520621999211108090712 [doi]
PST - ppublish
SO  - Anticancer Agents Med Chem. 2022;22(11):2080-2090. doi: 
      10.2174/1871520621999211108090712.